|
⚲
|
| RP Management LLC
✚
| |
|---|---|
| CRD # | 161569 |
| SEC # | 801-74235 |
| CIK # | 0001507673 |
| AUM | $17.6 BB (2024-03-28) |
| Employees | 75 (41% Investors, 0% Brokers) |
| Phone | 212-883-0200 |
| Address | 110 East 59th Street, Suite 3300 New York, NY 10022 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($BB) |
|---|
| Sector | Form 13F Holdings | Cap ($MM) | Value ($MM) |
|---|---|---|---|
| BHVN | 10,260.1 | 101.9 | |
| CYTK | 4,051.3 | 53.1 | |
| BCRX | 1,941.2 | 23.8 | |
| VIRX | 125.2 | 0.0 | |
| Holdings by Sector ($MM) |
|---|
| Type | Form D Funds | Date | Sold ($MM) | AUM ($MM) |
|---|---|---|---|---|
| PE | Royalty Pharma Select | [2021-04-29] | 40.9 | |
| HF | RPI Intermediate Finance Partnership LP | [2021-04-29] | 10.4 | 1,682.8 |
| PE | RPI International Holdings 2019 LP | [2020-03-27] | 0.0 | 1,046.3 |
| PE | RPI International Partners 2019 LP | [2020-03-27] | 0.0 | 22.2 |
| PE | RPI US Partners 2019 LP | [2020-03-27] | 0.0 | 1,452.1 |
| PE | RPS Biopharma Holdings LP | [2020-03-27] | 149.6 | 32.8 |
| PE | RPS Biopharma Holdings LP | 2018-03-29 | 72.8 | |
| PE | RPS Biopharma Investments LP | [2018-03-29] | 164.5 | 29.6 |
| PE | Royalty Pharma Cayman Holdings 2008 LP | [2012-02-15] | 0.7 | |
| PE | Royalty Pharma Cayman Holdings LP | 2012-02-15 | 61.9 | |
| View All | ||||
| AUM Breakdown | Accounts | AUM ($BB) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 19 | 17.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 19 | 17.0 |
| By Discretionary | ||
| Discretionary | 19 | 17.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 19 | 17.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 13.9 | |
| United States Persons | 3.1 | |
| Total | 19 | 17.0 |
| Form D Directors | # Filings | # Firms | 2011 - 2024 |
|---|---|---|---|
| Rory Riggs | 35 | ||
| Pablo Legorreta | 12 | ||
| RPI GP 2019 LP | 3 | ||
| Pharma Management Cayman Ltd | 3 |
| EDGAR Form | CIK | 2011 - 2024 |
|---|---|---|
| 13F-HR | [0001507673] | |
| 3 | [0001507673] | |
| 4 | [0001507673] |
| Form 3/4/5 Subject | 2011 - 2024 |
|---|---|
| RPI Finance Trust | |
| Legorreta Pablo G. | |
| Royalty Pharma Investments 2019 ICAV | |
| RP Management, LLC | |
| Epizyme, Inc. |
| Comparable Firms | State | AUM ($BB) |
|---|---|---|
|
Alpha Wave Global LP
✚
|
NY | 19.4 |
|
Diameter Capital Partners LP
✚
|
NY | 18.3 |
|
OrbiMed Advisors LLC
✚
|
NY | 18.2 |
|
Lone Pine Capital LLC
✚
|
CT | 17.5 |
|
Omers Infrastructure US Limited
✚
|
NY | 17.3 |
|
Abry Partners II LLC
✚
|
MA | 17.1 |
|
Post Advisory Group LLC
✚
|
CA | 16.7 |
|
AIP LLC
✚
|
NY | 16.7 |
|
Alcentra NY LLC
✚
|
NY | 16.4 |
|
Deerfield Management Company LP Series C
✚
|
NY | 16.1 |